Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | MMP1 | P03956 | 3/20 | 0.67 |
| ▸ | MMP2 | P08253 | 3/20 | 0.67 |
| ▸ | MMP9 | P14780 | 3/20 | 0.67 |
| ▸ | EGFR | P00533 | 3/20 | 0.67 |
| ▸ | SLC6A19 | Q695T7 | 1/20 | 0.67 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL975477 | 1.00 | KMT2A (0.69) | KMT2AMMP1MMP2MMP9EGFR | |
| SCHEMBL8099537 | 0.88 | KMT2A (0.58) | KMT2AMMP1MMP2MMP9EGFR | |
| SCHEMBL14080852 | 0.88 | HDAC3 (0.67) | KMT2AMMP1MMP2MMP9EGFR | |
| N-Propylcinnamamide SCHEMBL29040560 | 0.86 | EGFR (0.77) | KMT2AMMP1MMP2MMP9EGFR | |
| N-Propylcinnamamide SCHEMBL28438139 | 0.86 | EGFR (0.77) | KMT2AMMP1MMP2MMP9EGFR | |
| N-Propylcinnamamide SCHEMBL12224106 | 0.86 | EGFR (0.77) | KMT2AMMP1MMP2MMP9EGFR | |
| SCHEMBL11590847 | 0.85 | KMT2A (0.86) | KMT2AMMP1MMP2MMP9EGFR | |
| SCHEMBL25510259 | 0.85 | KMT2A (0.73) | KMT2AMMP1MMP2MMP9EGFR | |
| Catechol SCHEMBL28831689 | 0.84 | MMP1 (0.62) | KMT2AMMP1MMP2MMP9SLC6A19 | |
| SCHEMBL8661061 | 0.84 | MAOB (0.69) | MMP1MMP2MMP9SLC6A19HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108794691-A | Non-crosslinked polyolefin composition for cable | 重庆文理学院 | 2018-11-13 | — | — | CN | claimed |
| JP-4828407-B2 | — | — | 2011-11-30 | — | — | JP | claimed |
| EP-1594869-A2 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | Targacept, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| WO-2004076449-A2 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | TARGACEPT, INC. (US) | 2004-09-10 | — | — | WO | claimed |
| CN-113462278-B | Varnish composition, method for producing polyimide resin, and additive | 东京应化工业株式会社 | 2024-06-07 | — | — | CN | disclosed |
| CN-115093373-A | 1, 5-disubstituted-3-fluoroalkyl-1, 2, 4-triazole compound and preparation method and application thereof | 江苏省中国科学院植物研究所 | 2022-09-23 | — | — | CN | disclosed |
| CN-113462278-A | Varnish composition, method for producing polyimide resin, and additive | 东京应化工业株式会社 | 2021-10-01 | — | — | CN | disclosed |
| CN-106496411-B | A kind of purposes of the hydrophobic associated polymer with a variety of ring structure side chains and preparation method thereof with it | 中国海洋大学 | 2018-11-23 | — | — | CN | disclosed |
| EP-2994470-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | Principia Biopharma Inc. (US) | 2016-03-16 | — | — | EP | disclosed |
| WO-2014182829-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-11-13 | — | — | WO | disclosed |
| EP-2268614-B1 | METHOD FOR PRODUCING BETA-MERCAPTO CARBOXYLIC ACIDS | SHOWA DENKO KK (JP) | 2013-05-15 | — | — | EP | disclosed |
| US-8258340-B2 | Method for producing β-mercapto carboxylic acids | SHOWA DENKO K.K. (JP) | 2012-09-04 | — | — | US | disclosed |
| US-20110015436-A1 | METHOD FOR PRODUCING BETA-MERCAPTO CARBOXYLIC ACIDS | SHOWA DENKO K.K. (JP) | 2011-01-20 | — | — | US | disclosed |
| EP-2268614-A1 | METHOD FOR PRODUCING BETA-MERCAPTO CARBOXYLIC ACIDS | Showa Denko K.K. (JP) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009113711-A1 | METHOD FOR PRODUCING -MERCAPTO CARBOXYLIC ACIDS | SHOWA DENKO K.K. (JP) | 2009-09-17 | — | — | WO | disclosed |
| US-20090131657-A1 | PROCESS FOR ALKENYLATING CARBOXAMIDES | BASF SE (DE) | 2009-05-21 | — | — | US | disclosed |
| US-20050131101-A1 | Ink composition and inkjet recording method | FUJI PHOTO FILM CO., LTD. | 2005-06-16 | — | — | US | disclosed |
| EP-1392644-A1 | CINNAMIDE DERIVATIVES AS KCNQ POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002096858-A1 | CINNAMIDE DERIVATIVES AS KCNQ POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-12-05 | — | — | WO | disclosed |
| CN-1026816-C | Fluid dynamic bearing with continuous beam mounting bearing surface | IDE RUSSELL D (US) | 1994-11-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015436-A1 | METHOD FOR PRODUCING BETA-MERCAPTO CARBOXYLIC ACIDS | CBS, ALDH7A1, CBR1 | KMT2A 2360/4885MMP1 1901/4885MMP2 3854/4885 |
| US-20090131657-A1 | PROCESS FOR ALKENYLATING CARBOXAMIDES | PRMT5, CYC1, CBR3 | KMT2A 41/4885MMP1 4446/4885MMP2 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.